Importantly, JHU083, as a DON prodrug, blocks the glutaminase (deamidase) activity of CAD and overcomes the toxicity issues of DON by selectively targeting tumor microenvironment23, demonstrating its therapeutic potential for future clinical evaluation. This evidence concerns the gene CTSA and neoplasm.